Earnings History Data for Vyant Bio, Inc. (VYNT) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Vyant Bio, Inc.

VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. VYANT BIO INC., formerly known as Cancer Genetics Inc., is based in CHERRY HILL, N.J.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
15-11-2022	PM		VYNT	Vyant Bio	9.00	-0.62	-0.14	0.00	Vyant Bio GAAP EPS of -$0.62 beats by $0.08, revenue of $0.15M [11/15/2022 8:22 AM]	1.55	0.04 (2.31%)	1.48	-0.03 (-2.31%)	1.35 - 11.35	30,763	40,000	100
Vyant Bio GAAP EPS of -$0.62 beats by $0.08, revenue of $0.15M [11/15/2022 8:22 AM]
22-08-2022	AH	4:00 PM ET (Aug 22)	VYNT	Vyant Bio	23.00	-0.15	-0.15	0.00	Vyant Bio GAAP EPS of -$0.20, revenue of $0.17M [8/22/2022 4:12 PM]	9.57	-0.55 (-5.43%)	14.81	-0.16 (-1.07%)	4.61 - 25.25	167,743	130,000	121
Vyant Bio GAAP EPS of -$0.20, revenue of $0.17M [8/22/2022 4:12 PM] Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights [Aug-22-22 04:10PM] Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022 [Aug-19-22 09:29AM]
30-03-2022	PM	Before the open (Mar 30)	VYNT	Vyant Bio	34.00	N/A	-0.16	0.00	Vyant Bio GAAP EPS of -$1.81, revenue of $1.15M [3/30/2022 8:00 AM]	1.60	0.25 (18.64%)	1.72	0.37 (27.41%)	0.82 - 5.12	16,576,842	140,000	7,346,005
Vyant Bio spikes on deal to develop Parkinson’s Disease therapies [3/29/2022 5:15 PM] Vyant Bio GAAP EPS of -$1.81, revenue of $1.15M [3/30/2022 8:00 AM] Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinsons Disease [Mar-29-22 05:00PM] Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business Highlights [Mar-30-22 07:50AM] Vyant Bio forms Parkinson's drug partnership, seeks buyer for its CRO business [Mar-30-22 01:00PM]
16-08-2021	AH	After the close (Aug 16)	VYNT	Vyant Bio, Inc.	77.97	-0.14	0.00	-0.82		2.41	-0.01 (-0.41%)	2.52	0.10 (4.13%)	2.11 - 17.50	109,494	140,000	1,424
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates [Aug-16-21 04:01PM]
17-05-2021	AH		VYNT	Vyant Bio, Inc.	96.52	-0.85	0.00	-0.56	Vyant Bio reports Q1 results [5/17/2021 5:21 PM]	3.33	-0.03 (-0.89%)	3.30	-0.06 (-1.79%)	2.11 - 17.50	666,868	1,230,000	52,654
Vyant Bio reports Q1 results [5/17/2021 5:21 PM] Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update [May-17-21 05:15PM] Vyant Bio Inc to Host Earnings Call [May-18-21 06:45AM]